These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34008887)

  • 1. Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease.
    Toffoli M; Higgins A; Lee C; Koletsi S; Chen X; Eberle M; Sedlazeck FJ; Mullin S; Proukakis C; Schapira AHV
    Mov Disord; 2021 Jun; 36(6):1456-1460. PubMed ID: 34008887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease.
    Higgins AL; Toffoli M; Mullin S; Lee CY; Koletsi S; Avenali M; Blandini F; Schapira AH
    Neurodegener Dis Manag; 2021 Dec; 11(6):451-458. PubMed ID: 34666501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Features of
    Malek N; Weil RS; Bresner C; Lawton MA; Grosset KA; Tan M; Bajaj N; Barker RA; Burn DJ; Foltynie T; Hardy J; Wood NW; Ben-Shlomo Y; Williams NW; Grosset DG; Morris HR;
    J Neurol Neurosurg Psychiatry; 2018 Jul; 89(7):702-709. PubMed ID: 29378790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes.
    Greuel A; Trezzi JP; Glaab E; Ruppert MC; Maier F; Jäger C; Hodak Z; Lohmann K; Ma Y; Eidelberg D; Timmermann L; Hiller K; Tittgemeyer M; Drzezga A; Diederich N; Eggers C
    Mov Disord; 2020 Dec; 35(12):2201-2210. PubMed ID: 32853481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset.
    Schierding W; Farrow S; Fadason T; Graham OEE; Pitcher TL; Qubisi S; Davidson AJ; Perry JK; Anderson TJ; Kennedy MA; Cooper A; O'Sullivan JM
    Mov Disord; 2020 Aug; 35(8):1346-1356. PubMed ID: 32557794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease.
    Galper J; Balwani M; Fahn S; Waters C; Krohn L; Gan-Or Z; Dzamko N; Alcalay RN
    Mov Disord; 2021 Jun; 36(6):1451-1455. PubMed ID: 33570220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review.
    Filippi M; Balestrino R; Basaia S; Agosta F
    Mov Disord; 2022 Jul; 37(7):1375-1393. PubMed ID: 35521899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk.
    Straniero L; Rimoldi V; Monfrini E; Bonvegna S; Melistaccio G; Lake J; Soldà G; Aureli M; Shankaracharya ; Keagle P; Foroud T; Landers JE; Blauwendraat C; Zecchinelli A; Cilia R; Di Fonzo A; Pezzoli G; Duga S; Asselta R
    Mov Disord; 2022 Jun; 37(6):1202-1210. PubMed ID: 35262230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanopore sequencing of the glucocerebrosidase (GBA) gene in a New Zealand Parkinson's disease cohort.
    Graham OEE; Pitcher TL; Liau Y; Miller AL; Dalrymple-Alford JC; Anderson TJ; Kennedy MA
    Parkinsonism Relat Disord; 2020 Jan; 70():36-41. PubMed ID: 31809948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
    Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Glinka T; Goldstein O; Kestenbaum M; Cedarbaum JM; Mabrouk OS; Fraser KB; Shirvan JC; Orr-Urtreger A; Mirelman A; Thaler A
    Mov Disord; 2022 Jan; 37(1):190-195. PubMed ID: 34550621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.
    Avenali M; Cerri S; Ongari G; Ghezzi C; Pacchetti C; Tassorelli C; Valente EM; Blandini F
    Mov Disord; 2021 May; 36(5):1267-1272. PubMed ID: 33617695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intronic Haplotypes in GBA Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup.
    O'Sullivan JM; den Heijer JM; Groeneveld GJ; Cooper AA
    Mov Disord; 2021 Jun; 36(6):1468-1470. PubMed ID: 34002417
    [No Abstract]   [Full Text] [Related]  

  • 14. β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease.
    Moraitou M; Hadjigeorgiou G; Monopolis I; Dardiotis E; Bozi M; Vassilatis D; Vilageliu L; Grinberg D; Xiromerisiou G; Stefanis L; Michelakakis H
    Mol Genet Metab; 2011; 104(1-2):149-52. PubMed ID: 21745757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations.
    Caminiti SP; Carli G; Avenali M; Blandini F; Perani D
    Mov Disord; 2022 Jan; 37(1):106-118. PubMed ID: 34596920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: A Kin Cohort Study.
    Balestrino R; Tunesi S; Tesei S; Lopiano L; Zecchinelli AL; Goldwurm S
    Mov Disord; 2020 Nov; 35(11):2111-2114. PubMed ID: 32767585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource.
    Iwaki H; Leonard HL; Makarious MB; Bookman M; Landin B; Vismer D; Casey B; Gibbs JR; Hernandez DG; Blauwendraat C; Vitale D; Song Y; Kumar D; Dalgard CL; Sadeghi M; Dong X; Misquitta L; Scholz SW; Scherzer CR; Nalls MA; Biswas S; Singleton AB; ; ;
    Mov Disord; 2021 Aug; 36(8):1795-1804. PubMed ID: 33960523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the detection of GBA missense mutations and other variants using the Oxford Nanopore MinION.
    Leija-Salazar M; Sedlazeck FJ; Toffoli M; Mullin S; Mokretar K; Athanasopoulou M; Donald A; Sharma R; Hughes D; Schapira AHV; Proukakis C
    Mol Genet Genomic Med; 2019 Mar; 7(3):e564. PubMed ID: 30637984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.
    Szwedo AA; Dalen I; Pedersen KF; Camacho M; Bäckström D; Forsgren L; Tzoulis C; Winder-Rhodes S; Hudson G; Liu G; Scherzer CR; Lawson RA; Yarnall AJ; Williams-Gray CH; Macleod AD; Counsell CE; Tysnes OB; Alves G; Maple-Grødem J;
    Mov Disord; 2022 May; 37(5):1016-1027. PubMed ID: 35106798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fiber-Specific White Matter Alterations in Parkinson's Disease Patients with GBA Gene Mutations.
    Andica C; Kamagata K; Uchida W; Saito Y; Takabayashi K; Hagiwara A; Takeshige-Amano H; Hatano T; Hattori N; Aoki S
    Mov Disord; 2023 Nov; 38(11):2019-2030. PubMed ID: 37608502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.